APOA4 and cardiovascular disorder: Following the body mass index (BMI) adjustment, in ESRD patients with BMI > 23 kg m2, ApoA-IV was associated with all-cause mortality, heart rate mortality, sudden cardiac death, cerebrovascular events, and cardiovascular disorders [31].